Finally, we showed that circCDYL, which is positively correlated with good clinical outcomes in BC, interacts with IGF2BP1 and IGF2BP2 in BC cell lines and that circCDYL and RBP KD perturb hallmarks of cancer gene sets and, specifically, that circCDYL KD affects the expression of key tumor genes, e.g., TP53 and MYC. This evidence concerns the gene IGF2BP1 and breast cancer.